

D - 42 - - 42 - NI - - - -

## **Ocrevus**

## **Prior Authorization Request**

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

| tient's Name:   | Date:  |
|---|--|
| tient's ID:   | Patient's Date of Birth:   |
| iysician's Name:  | NPI#:  |
| ecialty:  | NPI#:  |
| ecialty:  | Physician Office Fax:  |
| eferring Provider Info: 🗖 Same as Requesting Pro                  | vider  |
| nme:  | NPI#:  |
| x:  | Phone:   |
| endering Provider Info:  Same as Referring Prov                   |  |
| nme:<br>x:  | NPI#:<br>Phone:  |
|   | nits in accordance with FDA-approved labeling,                         |
|   | r evidence-based practice guidelines.                                  |
| equired Demographic Information:                                  |  |
| Patient Weight:kg   |  |
| Patient Height:cm   |  |
| ug Information:   |  |
| Strength/Measure  | Units $\square$ ml $\square$ Gm $\square$ mg $\square$ ea $\square$ Un |
| Directions(sig)   | Route of administration  |
| Dosing frequency  | _  |
|   |  |
| te of Service Questions:  Indicate the site of service requested: |  |
| ☐ On Campus Outpatient Hospital                                   | ☐ Off Campus Outpatient Hospital                                       |
| ☐ Home based setting, <i>skip to Criteria Questions</i>           | ☐ Community office, <i>skip to Criteria Questions</i>                  |
| ☐ Ambulatory infusion site, <i>skip to Criteria Questi</i>        |  |
| Is the patient less than 18 years of age?                         |  |
| ☐ Yes, skip to Clinical Criteria Questions                        |  |
| □ No  |  |
| Has the patient experienced an adverse event with the             |  |

Send completed form to: Priority Partners Fax: 1-866-212-4756

rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Ocrevus SGM 1707-A – 12/2022.

| Pre                    | escriber or Authorized Signature Date (mm/dd/yy)   |
|------------------------|--|
|                        | ttest that this information is accurate and true, and that documentation supporting this formation is available for review if requested by Priority Partners.  |
| 7.                     | Is the patient experiencing disease stability or improvement while receiving the requested medication?  ☐ Yes ☐ No   |
| 6.<br>7                | Is this a request for continuation of therapy? $\square$ Yes $\square$ No If No, no further questions  |
|                        | If the patient is less that 18 years of age, has the prescriber evaluated the risks and benefits or treatment and attests the benefits outweigh the risks?   No  |
|                        | Will the requested medication be prescribed by or in consultation with a neurologist?   Yes  No  |
|                        | (Note: Ampyra and Nuedexta are not disease modifying.) ☐ Yes ☐ No  |
| <ol> <li>3.</li> </ol> | Is the patient taking the requested medication with any other disease modifying multiple sclerosis (MS) agent?   |
| 2.                     | ☐ Other, please specify  |
|                        | iteria Questions:  What is the diagnosis?  ☐ Relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse)  ☐ Primary progressive multiple sclerosis  ☐ Clinically isolated syndrome   |
| H.                     | Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?  **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.  |
| G.                     | Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting clinical documentation</i> . □ Yes, <i>skip to Clinical Criteria Questions</i> □ No  |
| F.                     | Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? <i>ACTION REQUIRED: If</i> 'Yes', please attach supporting clinical documentation.  □ Yes, skip to Clinical Criteria Questions □ No  |
| E.                     | Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting clinical documentation</i> .  □ Yes, <i>skip to Clinical Criteria Questions</i> □ No   |
| D.                     | Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?  **ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.**  D Yes, skip to Clinical Criteria Questions D No |
|                        | seizures) during or immediately after an infusion? <i>ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.</i> $\square$ Yes, <i>skip to Clinical Criteria Questions</i> $\square$ No   |

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC Ocrevus SGM 1707-A – 12/2022.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076